09:42 AM EST - Medicenna Therapeutics Corp. : Today announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $1.13.
